The mission of the Dermatology Summit is to build a community of people who are excited about innovation in dermatology.
This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Executive Partner Apollo Health Ventures Associate Clinical Professor of Medicine, Division of Dermatology David Geffen School of Medicine at UCLA
+ Click here to View Biography
Biography
Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently an Executive Partner at Apollo Health Ventures. Previously Frederick was the CEO and member of the board of directors of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and rare diseases. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.
Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, part of Advancing Innovation in Dermatology, a non-profit organization.
Tom Davidson
Partner PJT Partners
+ Click here to View Biography
Biography
Tom is a partner in the M&A Advisory business at PJT Partners, one of the premier independent investment banks. A member of PJT’s original partner group, Tom has built PJT’s Healthcare Advisory business into a leader within the Biopharma ecosystem. Tom has advised on many of the most significant US and cross-border Biopharma transactions including, over the last two years, six billion-dollar-plus transactions totaling in excess of fifty billion dollars. Included among these are the largest transactions announced globally in each of 2021 and 2022.
Prior to PJT Partners, Tom jointly led the global healthcare effort at Credit Suisse and was a Vice Chairman within the Investment Bank. Prior to Credit Suisse, Tom spent eleven years helping build the Healthcare Group at Merrill Lynch. He began his career in 1993 at McKinsey & Company. Tom graduated summa cum laude from Yale in 1991 and received his MBA from the Wharton School of the University of Pennsylvania in 1993.
Jasmina Jankicevic, MD, MSc, CCRP
Chief Medical Officer Innovaderm Research
+ Click here to View Biography
Biography
Dr. Jasmina Jankicevic is globally recognized as a thought leader in dermatology & medical aesthetics drug/device development. She has led clinical development in dermatology and medical aesthetics for CROs, pharma/biotech, medical device, and cosmetic companies. She has driven program strategy and implementation of 350+ clinical study protocols in 30+ indications while leading global cross-functional teams towards successful regulatory submissions, product launches, and innovative lifecycle management.
As a global expert in dermatology clinical development, Dr. Jankicevic has served as advisor to multiple companies on their way to global regulatory and commercial success of innovative therapeutic solutions for common and rare skin diseases, and aesthetic disorders.
Dr. Jankicevic holds Doctor of Medicine degree, Master of Medical Sciences degree, and Board-certification in Dermatology and Venereology from the University of Belgrade, Serbia. She is also a Certified Clinical Research Professional, and a trained journalist. Dr. Jankicevic is a sought-after speaker, and author of numerous articles in peer-reviewed and trade journals.
Sergio Rossi
Managing Director & Partner Boston Consulting Group
+ Click here to View Biography
Biography
Mr. Rossi is Global Topic Leader in BCG’s Medical Aesthetics and a core member of the Health Care practice with a focus on Corporate Strategy and Marketing & Sales themes. He has over 15 years of experience in growth strategy, portfolio analysis, commercial models, GTM, pricing, loyalty programs, and digital. Mr. Rossi has led over 40 projects for multiple medical aesthetics / skincare / beauty / breast implants companies.
Prior to joining BCG, Mr. Rossi worked at Pfizer Ltd. for several years as a brand manager and, previously, as a business analyst in the strategy practice of Accenture. He holds an MBA from SDA Bocconi School of Management and a M.Sc. in Aerospace Engineering from Politecnico di Torino/Princeton University.
Seth Orlow, MD, PhD, FAAD
Senior Advisor Pharus Advisors, LLC Professor & Chair of Dermatology NYU Grossman School of Medicine
+ Click here to View Biography
Biography
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Alan D. Widgerow, MBBCh, MMed, FCS, FACS
Chief Scientific Officer Galderma Head Skin Science Institute of Innovation Head Alastin Innovations
+ Click here to View Biography
Biography
Alan Widgerow is a plastic surgeon who ran a solo private practice in South Africa for over 20 years. He has held various positions in numerous academic and professional associations including that of President of the Association of Plastic and Reconstructive surgery of Southern Africa (APRSSA). He is author of over 180 plastic surgical related publications and 2 books. He was also the founder and medical director of 13 wound clinics in South Africa. Prof Widgerow relocated to Irvine California in Dec 2009 to pursue his interests in medical device innovations, cosmeceuticals and wound care, but he still plays an active role in academic medicine world-wide. In 2012 he was appointed to the Faculty of the University of California Irvine Plastic Surgery Dept as Full Adjunct Professor and Director of the Center for Tissue Engineering and in 2021 was appointed as its Division Chief of Research. He is involved in multiple projects related to adipose derived stem cell and adipose decellularized matrix, wound healing and transplantation. In 2018 he was awarded the Distinguished Faculty Mentor of the year Award by the Institute for Clinical and Translational Science, UCI. Dr Widgerow has developed and licensed multiple products in the US and South African markets. In 2015 he joined ALASTIN Skincare, Inc. an early start up professional skin care company as their Chief Medical Officer. Over the past 6 years he has spearheaded the scientific innovations team introducing multiple new products based on novel wound healing pathways. The resulting products have been validated with gene expression, in vitro testing, biopsies, and multiple clinical trials resulting in a range of products that have surpassed previous scientific validations in this space. He continues to pursue patented novel concepts, peptide technologies and vigorous testing thus contributing to Alastin Skincare’s position as the fastest growing professional skin care company in the US for the past 4 years. In 2021 Alastin Skincare was acquired by Galderma and in June 2022 Dr Widgerow was appointed Chief Scientific Officer Galderma where he is involved in Ax, Rx and Cx product science research and development.
Program
9:00AM
Registration and Networking Café
11:00AM
Networking Lunch
12:00PM
Program*
* Presentation order subject to change
6:00PM
Reception
Entrepreneurial Company Showcase
The program committee is accepting Entrepreneurial Company Showcase applications until September 25. Eligibility guidelines, details and the online submission form can be accessed below.
Executive Partner Apollo Health Ventures Associate Clinical Professor of Medicine, Division of Dermatology David Geffen School of Medicine at UCLA
+ Click here to View Biography
Biography
Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently an Executive Partner at Apollo Health Ventures. Previously Frederick was the CEO and member of the board of directors of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and rare diseases. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.
Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, part of Advancing Innovation in Dermatology, a non-profit organization.
William Ju, MD, FAAD
President & Founding Trustee Advancing Innovation in Dermatology, Inc.
+ Click here to View Biography
Biography
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Seth Orlow, MD, PhD, FAAD
Senior Advisor Pharus Advisors, LLC Professor & Chair of Dermatology NYU Grossman School of Medicine
+ Click here to View Biography
Biography
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Kristen B. Slaoui, PhD
Chief Corporate Development Officer Galderma
+ Click here to View Biography
Biography
Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.
Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.
Christina Weng, MD, FAAD
Senior Medical Director Kira Pharmaceuticals
+ Click here to View Biography
Biography
Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is currently the Medical Director of Kira Pharmaceuticals, a Boston-based global biotech company developing innovative complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she serves as Chief Strategy Officer. As an Instructor in Dermatology at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital (MGH), she specializes in melanoma and pigmentary disorders.
Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH.
Christina’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Her work additionally explores strategies for cutaneous drug delivery. Christina’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research support and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health.
The Dermatology Summit utilizes a conference app for meeting materials and networking, available on both Apple and Android devices for all registered attendees.
The app will serve as our networking portal. Upon logging into the app, you will be able to update your profile, view the list of registered attendees and communicate with other attendees via chat. A 1:1 networking room will be available at the conference for your use should you wish to set up meetings on your own with other attendees.
The app will launch in December, and you will receive an email with instructions at that time.
If registered by October 27, 2023 – $795
Registration after October 27, 2023 – $995
What is included in the registration fees?
Conference registration includes:
Networking Café
Networking Lunch
Networking Breaks
All Conference Sessions
Access to Conference App for Networking Opportunities
Evening Networking Cocktail Reception
Health and Safety Release
Advancing Innovation in Dermatology, Inc. (“AID”) looks forward to welcoming attendees in person for the 2024 Dermatology Summit scheduled for January 7, 2024. Health and safety remain a top priority, and AID is working with the Hyatt Regency San Francisco to plan for on-site precautions and mitigations for the event, including related to COVID-19. Attendees should follow the CDC’s Isolation and Precautions for People with COVID-19 guidance.
In all events, attendees must follow all federal, state and local health and safety guidance, including guidance on when to quarantine and wear a mask (AID reserves the right to update its health and safety policies in its discretion from to time to time). Of course, given the highly contagious nature of COVID-19 and its ability to spread by person-to-person contact, the event carries a risk of exposure to COVID-19 to attendees. By attending the event, attendees hereby agree to accept such risk and release and waive any and all claims, now known or hereafter known, against AID, its officers, directors, trustees, employees and agents, as well as its successors and assigns (collectively, the Releasees”) on account of any exposure to COVID-19 or any other illness or infection that may be associated with the event caused by any of the Releasees (except claims for willful misconduct or liability that cannot be released by applicable law).
How do I become a Sponsor?
If you are interested in a sponsorship opportunity, please contact Amanda Pacia at amanda.pacia@advancing-derm.org, for the sponsorship overview and level pricing.
Our app will launch in December, and you will receive an email at that time with download instructions.
Where can I make hotel reservations?
There are several hotels within a short distance from the Hyatt Regency Embarcadero, where the Dermatology Summit will take place.
Hotel
Address
Phone
Hyatt Regency San Francisco
5 Embarcadero Center
415-788-1234
Grand Hyatt San Francisco
345 Stockton Street
415-398-1234
Beacon Grand
450 Powell Street
866-377-9412
Westin St. Francis
335 Powell Street
415-397-7000
JW Marriott
515 Mason Street
415-771-8600
Hilton San Francisco Union Sq.
333 O’Farrell Street
415-771-1400
Ritz-Carlton
600 Stockton Street
415-296-7465
Marriott Union Sq.
480 Sutter Street
415-398-8900
What is the dress code?
Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.
I am a Sponsor. How do I redeem my contracted complimentary registration(s)?
After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 8, 2023. If you have not yet received the email, please contact Faye Silag at faye.silag@advancing-derm.org.
Cancellation Policy
Requests for registration fee cancellations for the conference must be received on or before December 8, 2023. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 8, 2023. Written notice of your cancellation should be sent to jamie.breslin@advancing-derm.org with a copy to support@advancing-derm.org.
Force Majeure
No damages or refunds shall be due for a failure of performance or because of a delay or cancellation by the occurrence of any contingency beyond the reasonable control of Host. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, strikes, labor disputes, picketing or work stoppage (actual or threatened), failure or delay in transportation, an epidemic, pandemic or disease, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.